Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravenous ascorbic acid/vitamin C Clear all
Completed Not applicable Interventional

The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients

NCT03938584
View directory record Official record
Conditions
Vitamin C Deficiency, Smoking, Surgery, Surgery--Complications, Wound, Wound Complication, Wound Infection, Wound Dehiscence, Wound of Skin, Mandible Fracture, Mandible Open Fracture, Mandible Closed Fracture, Mandibular Fractures, Ascorbic Acid Deficiency, Oxidative Stress, Inflammation
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

Burn Micronutrient Repletion Pilot Study

NCT00879723
View directory record Official record
Conditions
Burn
Interventions
Vitamin and Mineral supplementation
Dietary Supplement
Lead sponsor
Southern Illinois University
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer

NCT00954525
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine and Erlotinib, Intravenous Vitamin C
Drug · Dietary Supplement
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 3 Interventional Results available

Vitamin C, Thiamine, and Steroids in Sepsis

NCT03509350
View directory record Official record
Conditions
Sepsis
Interventions
Vitamin C, Thiamine, Hydrocortisone, Vitamin C Placebo, Thiamine Placebo, Hydrocortisone Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
43
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Sep 19, 2026, 5:35 AM EDT
Active, not recruiting Phase 1 Interventional

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

NCT02311621
View directory record Official record
Conditions
Neuroblastoma, Ganglioneuroblastoma
Interventions
Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells), Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells)
Biological
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Months to 26 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2038
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 19, 2026, 5:35 AM EDT
Completed No phase listed Observational

Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.

NCT03913468
View directory record Official record
Conditions
Septic Shock, Ascorbic Acid Deficiency
Interventions
Intravenous Ascorbic Acid
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 90 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study of Intravenous Ascorbic Acid

NCT02534753
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Ascor L 500® (Ascorbic Acid Injection, USP)
Drug
Lead sponsor
McGuff Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Sep 19, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

High Dose Vitamin C in the Critically Ill Patient

NCT01587963
View directory record Official record
Conditions
Shock
Interventions
Ascorbic Acid, Ringers Lactate or Normal Saline
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Sep 19, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer

NCT06493370
View directory record Official record
Conditions
Bladder Cancer
Interventions
Intravenous ascorbic acid/vitamin C
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Iowa City, Iowa • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 19, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

NCT02833701
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Ascorbic Acid, Bevacizumab, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Dietary Supplement · Biological · Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Sep 19, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT03418038
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions
Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography
Dietary Supplement · Drug · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
4
States / cities
Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

NCT03433781
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Vitamin C
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 19, 2026, 5:35 AM EDT
Completed No phase listed Observational

Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C

NCT05612867
View directory record Official record
Conditions
Burns, Ascorbic Acid Deficiency, Burn Shock, Burn Degree Second, Burn Degree Third, Fluid and Electrolyte Imbalance
Interventions
Vitamin C
Dietary Supplement
Lead sponsor
Arrowhead Regional Medical Center
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Colton, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Intravenous Ascorbic Acid

NCT01833351
View directory record Official record
Conditions
Safety and Pharmacokinetics of Intravenous Ascorbate
Interventions
IV Vitamin C
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation

NCT04357782
View directory record Official record
Conditions
COVID-19, Hypoxia
Interventions
L-ascorbic acid
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Sep 19, 2026, 5:35 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19

NCT05045937
View directory record Official record
Conditions
Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Acute Bronchitis
Interventions
Ivermectin
Drug
Lead sponsor
Patrick Robinson
Other
Eligibility
12 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

NCT03613727
View directory record Official record
Conditions
Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
Interventions
Intravenous (IV) and oral Vitamin C
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 77 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 19, 2026, 5:35 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

NCT00228319
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Oral Ascorbic Acid, Paclitaxel, Carboplatin, Sodium Ascorbate, Oral Mixed natural Carotenoids with Vitamin A, Vitamin E
Dietary Supplement · Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

NCT03508726
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
Ascorbate
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 2 Interventional Results available

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

NCT04291508
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions
Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

New Treatment Option for Pancreatic Cancer

NCT01364805
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Intravenous Vitamin C, Gemcitabine
Drug
Lead sponsor
Jeanne Drisko, MD, CNS, FACN
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 19, 2026, 5:35 AM EDT
Completed Phase 1 Interventional

Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women

NCT00862433
View directory record Official record
Conditions
Diabetes, Fatty Liver, Obesity, Healthy Volunteers
Interventions
Alpha tocopherol, Vitamin E, Vitamin C
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 19, 2026, 5:35 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC

NCT02905591
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Non-Small-Cell Lung Carcinoma, NSCLC
Interventions
Radiation Therapy, Paclitaxel, Carboplatin, Ascorbic Acid
Drug
Lead sponsor
Joseph J. Cullen, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 19, 2026, 5:35 AM EDT